FIELD: chemistry.
SUBSTANCE: present invention relates to novel xanthine derivatives of general formula (I) and their pharmaceutically acceptable salts which have HM74A receptor activity, which can be used in therapy for treating diabetic dyslipidemia, combined dyslipidemia, heart failure, hypercholesteremia, atherosclerosis, arteriosclerosis, hypertriglyceridemia, type II sugar diabetes, type I diabetes, insulin resistance, hyperlipidemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, stenocardia, chronic kidney disease, peripherical vascular disease or stroke. In compounds of formula (I) 
, R1 is hydrogen or methyl; R2 is unsubstituted H-C4-6 alkyl; and R3 is chlorine.
EFFECT: obtaining novel compounds and a pharmaceutical composition based on the said novel xanthine derivatives.
15 cl, 54 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIVE MEDICINAL AGENT | 2003 |
|
RU2328280C2 |
| AMIDO-SUBSTITUTED DERIVATIVES OF XANTHINE POSSESSING INHIBITORY EFFECT ON ACTIVITY OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK), METHOD FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION AND USING | 2003 |
|
RU2295525C2 |
| HYDROXYPURINE COMPOUNDS AND WAYS OF THEIR USE | 2015 |
|
RU2673458C1 |
| HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
| SUBSTITUTED PHENOXYACETIC ACIDS, THEIR ESTERS AND AMIDES CONTAINING 2,6-DIOXO-2,3,6,7-TETRAHYDRO-1H-PYRIN-8-YL FRAGMENTS - A ADENOSINE RECEPTOR ANTAGONISTS AND USE THEREOF | 2011 |
|
RU2477726C1 |
| NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND COSMETICS | 2015 |
|
RU2712971C2 |
| TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
| NOVEL CONDENSED DERIVATIVES OF IMIDAZOLE, INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USING BASED ON THEREOF | 2003 |
|
RU2297418C9 |
| TRICYCLIC COMPOUND AND JAK INHIBITOR | 2015 |
|
RU2674262C2 |
| SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2013 |
|
RU2607081C2 |
